Trial Profile
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Savolitinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SAFFRON
- Sponsors AstraZeneca; AstraZeneca AB
- 18 May 2023 Planned End Date changed from 3 Dec 2026 to 30 Nov 2026.
- 18 May 2023 Planned primary completion date changed from 18 Jul 2025 to 30 May 2025.
- 31 Aug 2022 Planned End Date changed from 30 Nov 2026 to 3 Dec 2026.